Iovance Biotherapeutics was the first drug developer to win FDA approval of an immune cell/T-cell therapy. The underlying ...

The Chronic Lymphocytic Leukemia Market is set for significant expansion over the next decade. Valued at USD 5.4 billion in 2025, the market is projected to grow to USD 10.3 billion by 2035, ...

Johns Hopkins scientists discovered a way to convert “immune-cold” tumors into “immune-hot” ones by activating key immune ...

Treatment with Sanofi's frexalimab was seen in a study to safely maintain disease control over 2.5 years in adults with ...

In experiments with mouse models of breast, pancreatic, and muscle cancers, researchers at Johns Hopkins All Children's Hospital report new evidence that a novel means of boosting the natural immune ...

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the Best Penny Stocks to Buy with the Highest Upside Potential. On September 8, ImmunityBio, Inc. (NASDAQ:IBRX) announced new findings from its Phase 2 ...

In experiments with mouse models of breast, pancreatic, and muscle cancers, researchers at Johns Hopkins All Children’s ...

A new review highlights sepsis-induced immunosuppression as a key driver of mortality, summarizing current research and ...

Discover which foods and strategies actually boost iron status and why the right dose and pairing can make the difference ...

Acute promyelocytic leukemia (APL) represents a paradigm of targeted therapy in hematologic malignancies. Once regarded as ...

SAN DIEGO (FOX 5/KUSI) — The National Weather Service (NWS) issued a Flood Watch for San Diego County and Southern California mountains, along with beach hazard statements, that will be in effect this ...

Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. Click here to read more.